The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Current Market Overview

• The subcutaneous immunoglobulin market is expanding swiftly.
• 2023 Market Size: $11.19 billion.
• 2024 Market Size: Expected to reach $12.72 billion, with a CAGR of 13.7%.
• Growth Drivers:
  • Increased prevalence of immunodeficiency disorders.
  • Rise in patient preference for home-based care.
  • Enhanced therapeutic efficacy.
  • Growth in awareness and diagnosis rates.
  • Favorable reimbursement policies.

Future Market Projections

• The market will continue to grow significantly.
• 2028 Market Size: Expected to reach $21.38 billion, with a CAGR of 13.9%.
• Growth Drivers:
  • Growing prevalence of neurological disorders.
  • Increasing prevalence of autoimmune diseases.
  • Rising awareness and acceptance of immunoglobulin therapy.
  • Expanding applications in neurology and dermatology.
  • Expansion of healthcare facilities.
• Major Trends:
  • Advancements in drug delivery systems.
  • Increasing demand for home infusion therapies.
  • Developments in antibody therapy.
  • Innovations in formulations and SCIG.

View More On The Subcutaneous Immunoglobulin (SCIG) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Impact of Secondary Immunodeficiency Diseases

Growing Prevalence and Market Impact

• Secondary Immunodeficiency Diseases: Conditions caused by external factors like aging, immunosuppressive treatments, and environmental toxins.
• Impact: These diseases necessitate subcutaneous immunoglobulin therapy, which strengthens the immune system and prevents infections.
• Example:
  • UK Health Security Agency Report (October 2023): 3,805 new HIV diagnoses in England in 2022, a 22% rise from the previous year.
• Conclusion: Increased prevalence of secondary immunodeficiency diseases drives market growth.

Rising Neurological Disorders

Contribution to Market Expansion

• Neurological Disorders: Includes conditions like Alzheimer’s, ALS, brain tumors, etc.
• Increasing Factors: Aging populations, environmental toxins, genetic predispositions, lifestyle changes.
• Therapeutic Benefits:
  • Modulates immune response.
  • Reduces inflammation.
  • Stabilizes neuromuscular junctions.
  • Slows disease progression and improves symptoms.
• Example:
  • Alzheimer’s Association Report (March 2022): 6.5 million Americans aged 65 and older living with Alzheimer’s dementia, projected to reach 13.8 million by 2060.
• Conclusion: Rising neurological disorders contribute to market growth.

Major Players in the Subcutaneous Immunoglobulin Market

Key Companies

• Major Companies:
  • Pfizer Inc.
  • Johnson & Johnson.
  • Prothena Corporation plc.
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Limited.
  • Amgen Inc.
  • Baxter International Inc.
  • CSL Behring.
  • Lonza Group.
  • Grifols S.A.
  • Octapharma AG.
  • Dr. Reddy’s Laboratories.
  • Intas Pharmaceutical Ltd.
  • Emergent BioSolutions Inc.
  • Bharat Serums and Vaccines Limited (BSV).
  • Kamada Pharmaceuticals.
  • CinnaGen Co.
  • Shire plc.

Advancements in SCIG Therapy for Primary Immunodeficiency Diseases

Innovative Products and Treatments

• Subcutaneous Human-klhw: A unique formulation for treating primary immunodeficiency diseases.
• Example:
  • Grifols S.A. (March 2022): Launched XEMBIFY 20% SCIG, designed for primary immunodeficiency.
  • Features:
    • Ready-to-use formulation.
    • Simplifies treatment process.
    • Increases patient convenience.
    • Stable at room temperature for up to 24 months.

Market Segmentation

Product Types and Applications

• By Product Type:
  • Immunoglobulin A (IgA).
  • Immunoglobulin G (IgG).
  • Immunoglobulin M (IgM).
• By Application:
  • Primary Immunodeficiency Disorders.
  • Autoimmune Diseases.
  • Neurological Disorders.
  • Other Applications.
• By End-Use:
  • Clinics.
  • Hospitals.
  • Homecare.
  • Other End-Uses.

Regional Insights

Geographic Market Dynamics

• Largest Region (2023): North America.
• Fastest-Growing Region (Forecast Period): Asia-Pacific.

The subcutaneous immunoglobulin market is set for continued growth, driven by increasing prevalence of various disorders and advancements in therapy and drug delivery systems.

Request A Sample Of The Global Subcutaneous Immunoglobulin (SCIG) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15935&type=smp